Repositorio Dspace

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe

Mostrar el registro sencillo del ítem

dc.contributor.author Grigorian-Shamagian, Lilian
dc.contributor.author Edel, Klaus
dc.contributor.author Esteve-Pastor, María
dc.contributor.author Acena, Álvaro
dc.contributor.author Silva, Claudia
dc.contributor.author Delgado-Silva, Joana
dc.contributor.author Ntaios, Georges
dc.contributor.author Demerouti, Eftychia
dc.contributor.author Brotons, Carlos
dc.date.accessioned 2025-11-21T08:41:41Z
dc.date.available 2025-11-21T08:41:41Z
dc.date.issued 2021-08-24
dc.identifier.citation Grigorian-Shamagian L, Edel K, Esteve-Pastor MA, Aceña Á, Silva C, Delgado-Silva J, et al. Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe. Front Cardiovasc Med. 24 de agosto de 2021;8:663361.
dc.identifier.issn 2297-055X
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/21888
dc.description.abstract The main objective of cardiovascular disease (CVD) prevention is to reduce morbidity and mortality. Despite recommendations on evidence-based pharmacological treatment and lifestyle changes, the control of CV risk factors such as hypertension or dyslipidaemia is not optimal. The use of a CV polypill, including guideline-recommended drugs, as a baseline therapy, may contribute to improving risk factors control either by improving the treatment adherence or by the synergistic effect of its components. The CNIC-Polypill is the first CV polypill approved in Europe as an effective strategy for secondary prevention, which contains acetylsalicylic acid, atorvastatin (in two optional doses), and ramipril (in three optional doses) in a single pill. The present practical clinical document aims to provide a guide for patient management after an acute coronary syndrome (ACS) or with chronic CVD (CCVD) with a strategy based on the CNIC-Polypill, also considering the need to add other therapies for a personalized treatment. The most suitable clinical scenarios for the CNIC-Polypill use are discussed: (a) in patients after an ACS at discharge, (b) in patients with CCVD (chronic coronary syndrome, stroke, or peripheral artery disease) with uncontrolled low-density lipoprotein cholesterol (LDL-c) and/or blood pressure levels and (c) in patients with CCVD with well-controlled risk factors to simplify treatment and reduce polypharmacy in the context of CCVD prevention.
dc.language.iso eng
dc.publisher FRONTIERS MEDIA SA
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/es/  *
dc.title Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 34504874
dc.relation.publisherversion https://www.frontiersin.org/articles/10.3389/fcvm.2021.663361/full
dc.identifier.doi 10.3389/fcvm.2021.663361
dc.journal.title Frontiers in Cardiovascular Medicine


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta